PUBLISHER: The Business Research Company | PRODUCT CODE: 1829929
PUBLISHER: The Business Research Company | PRODUCT CODE: 1829929
Acute care syndromic testing is a rapid molecular diagnostic approach that detects multiple pathogens simultaneously from a single patient sample. Primarily used in emergency and critical care settings, it enables quicker diagnosis of infectious diseases, leading to faster treatment decisions, improved patient outcomes, and reduced hospital stays.
The main disease types in the acute care syndromic testing market include respiratory diseases, gastrointestinal diseases, genitourinary diseases, tropical diseases, and others. Respiratory diseases affect the lungs, airways, and respiratory tract, causing symptoms such as coughing, shortness of breath, and fever. Various sample types used for testing include blood, urine, biofluids, stool, swabs, and more. The tests target bacteria, viruses, fungi, and parasites and are utilized in hospitals, clinical and diagnostic laboratories, research and academic institutions, and other healthcare settings.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The acute care syndromic testing market research report is one of a series of new reports from The Business Research Company that provides acute care syndromic testing market statistics, including the acute care syndromic testing industry's global market size, regional shares, competitors with a acute care syndromic testing market share, detailed acute care syndromic testing market segments, market trends and opportunities, and any further data you may need to thrive in the acute care syndromic testing industry. This acute care syndromic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The acute care syndromic testing market size has grown rapidly in recent years. It will grow from $4.08 billion in 2024 to $4.59 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to increase in awareness of antimicrobial resistance, rise in government funding for infectious disease, increase in investment in healthcare infrastructure, increase focus on syndromic testing, expansion of telemedicine and rise in infectious disease.
The acute care syndromic testing market size is expected to see rapid growth in the next few years. It will grow to $7.39 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to rising prevalence of infectious diseases, growing demand for faster diagnostic solutions, expansion of healthcare services, rising use of multiplex syndromic panels, and growing geriatric population. Major trends in the forecast period include shift toward point-of-care testing, integration of cloud-based platforms, adoption of multiplex panels, development of AI-powered tools, and automation in syndromic testing.
The forecast of 12.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply disruptions for multiplex polymerase chain reaction (PCR) cartridges from Singapore and automated sample prep modules from South Korea, slowing infectious disease diagnosis.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of infectious diseases is expected to drive the growth of the acute care syndromic testing market. Infectious diseases, caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites, can spread through human contact, animals, or the environment. Factors such as population growth, urbanization, global travel, antimicrobial resistance, and climate change are contributing to the rising incidence of these diseases, increasing the demand for effective diagnostic and treatment solutions. Acute care syndromic testing plays a crucial role in identifying pathogens and co-infections through multiplex molecular diagnostics, allowing for targeted treatment decisions. For example, in February 2024, the UK Health Security Agency reported that in week 4 of 2024, the influenza positivity rate rose to 16.6%, up from 14.0% the previous week. Influenza-like illness (ILI) consultations also increased, reaching 9.8 per 100,000 people compared to 7.5 per 100,000 in the prior week, while influenza hospitalizations climbed from 5.12 to 7.63 per 100,000. Consequently, the growing incidence of infectious diseases is fueling the expansion of the acute care syndromic testing market.
Leading companies in the acute care syndromic testing market are leveraging advancements in multiplex real-time polymerase chain reaction (PCR) technology to enhance diagnostic accuracy, enable rapid pathogen detection, streamline laboratory workflows, and reduce turnaround time. Multiplex real-time PCR is an advanced molecular diagnostic method that simultaneously detects and quantifies multiple pathogens or genetic targets in a single reaction, improving efficiency and accuracy in disease diagnosis. In April 2023, QIAGEN N.V., a Netherlands-based biotechnology company, launched the QIAstat-Dx syndromic testing solution in Japan. This system features a SARS-CoV-2 respiratory panel capable of detecting over 20 pathogens from a single sample. Using multiplex real-time PCR technology, it provides rapid results with minimal labor compared to traditional PCR assays. By the end of 2022, over 3,500 QIAstat-Dx systems had been installed worldwide, aiding in the diagnosis of respiratory, gastrointestinal, and meningitis-related conditions. Available in more than 100 countries, this system is improving global access to syndromic testing.
In May 2023, Applied BioCode, a US-based biotechnology company, partnered with Medline Industries to expand the distribution of the BioCode MDx-3000 System. This collaboration aims to enhance access to diagnostic testing for hospitals and reference laboratories across the U.S. Medline Industries LP, a US-based healthcare company specializing in medical supplies and healthcare services, will support the distribution of Applied BioCode's multiplex diagnostic solutions, further advancing syndromic testing capabilities.
Major players in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMerieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., and Applied BioCode Inc.
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in acute care syndromic testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute care syndromic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute care syndromic testing market consists of revenues earned by entities by providing services such as comprehensive pathogen detection, rapid turnaround time, and support for antimicrobial stewardship. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute care syndromic testing market also includes sales of blood collection tubes, or urine containers, PCR and RT-PCR machines, and reader devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Care Syndromic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute care syndromic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acute care syndromic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute care syndromic testing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.